Efficacy and Metabolic Influence on Blood-Glucose and Serum Lipid of Ziprasidone in the Treatment of Elderly Patients with First-Episode Schizophrenia

As the age of the population in China rises, the occurrence of first-episode of schizophrenia in elderly persons is also gradually increasing. However, studies examining selection of therapeutic drugs for this population are relatively few. To examine the therapeutic efficacy and metabolic influence...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Shanghai Jingshen Yixue 2017-04, Vol.29 (2), p.104-110
Hauptverfasser: Chen, Jing, Pan, Xingen, Qian, Mincai, Yang, Shoukai
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 110
container_issue 2
container_start_page 104
container_title Shanghai Jingshen Yixue
container_volume 29
creator Chen, Jing
Pan, Xingen
Qian, Mincai
Yang, Shoukai
description As the age of the population in China rises, the occurrence of first-episode of schizophrenia in elderly persons is also gradually increasing. However, studies examining selection of therapeutic drugs for this population are relatively few. To examine the therapeutic efficacy and metabolic influence on blood-glucose and serum lipid of ziprasidone in the treatment of elderly patients with first-episode schizophrenia. Using randomized grouping, 38 elderly patients with first-episode schizophrenia were randomly divided into the ziprasidone treatment group (i.e. the study group) and the olanzapine treatment group (i.e. the control group), with 19 cases in either group respectively. The positive and negative symptoms scale (PANSS) was used to evaluate the efficacy, and adverse drug reaction scale (TESS) was used to evaluate adverse drug reactions, at the points prior to the treatment, at the end of 4th, 8th, and 12th weeks of treatment, respectively. Fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), and low density lipoprotein (LDL-c) were also measured. There was no significant difference between the two groups in PANSS score at the end of week 4, week 8 and week 12. The curative effect on the two groups was similar. The results of repeated measure ANOVA showed that there were significant differences in FBG ( , =0.001), ,
doi_str_mv 10.11919/j.issn.1002-0829.217005
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5518257</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1925510992</sourcerecordid><originalsourceid>FETCH-LOGICAL-p181t-507c371534233dad9821e62d6fe11cecc3cf851c2a71a853be54f34bf266d0233</originalsourceid><addsrcrecordid>eNpVUctOHDEQ9CERIOAXIh9zmY3tGc_jEilBy0NaRCTIhcvIa7czjTz2xPYQbT6E72UID4W-tFRVXVVSE0I5W3He8e7L3QpT8ivOmChYK7qV4A1j8gM5eIP2yXFKd2yZpqo6yfbIvmibWtYtPyAPa2tRK72jyht6CVltg0NNL7x1M3gNNHj63YVgijM365Dgn_Aa4jzSDU5oaLD0FqeoEprggaKneQB6E0HlEXx-4tfOQHQ7-kNlXKBE_2Ae6CnGlIv1hCkYoNd6wL9hGiJ4VEfko1UuwfHLPiQ_T9c3J-fF5urs4uTbpph4y3MhWaPLhsuyEmVplOlawaEWprbAuQatS21bybVQDVetLLcgK1tWWyvq2rDl5pB8ffad5u0IRi_lonL9FHFUcdcHhf17xuPQ_wr3vZS8FbJZDD6_GMTwe4aU-xGTBueUhzCnnndikbKuE4v00_9ZbyGvzygfAWk3kHE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1925510992</pqid></control><display><type>article</type><title>Efficacy and Metabolic Influence on Blood-Glucose and Serum Lipid of Ziprasidone in the Treatment of Elderly Patients with First-Episode Schizophrenia</title><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Chen, Jing ; Pan, Xingen ; Qian, Mincai ; Yang, Shoukai</creator><creatorcontrib>Chen, Jing ; Pan, Xingen ; Qian, Mincai ; Yang, Shoukai</creatorcontrib><description>As the age of the population in China rises, the occurrence of first-episode of schizophrenia in elderly persons is also gradually increasing. However, studies examining selection of therapeutic drugs for this population are relatively few. To examine the therapeutic efficacy and metabolic influence on blood-glucose and serum lipid of ziprasidone in the treatment of elderly patients with first-episode schizophrenia. Using randomized grouping, 38 elderly patients with first-episode schizophrenia were randomly divided into the ziprasidone treatment group (i.e. the study group) and the olanzapine treatment group (i.e. the control group), with 19 cases in either group respectively. The positive and negative symptoms scale (PANSS) was used to evaluate the efficacy, and adverse drug reaction scale (TESS) was used to evaluate adverse drug reactions, at the points prior to the treatment, at the end of 4th, 8th, and 12th weeks of treatment, respectively. Fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), and low density lipoprotein (LDL-c) were also measured. There was no significant difference between the two groups in PANSS score at the end of week 4, week 8 and week 12. The curative effect on the two groups was similar. The results of repeated measure ANOVA showed that there were significant differences in FBG ( , =0.001), , &lt;0.001), TG(F =488.312, &lt;0.001), and LDL-c , &lt;0.001)between the study group and the control group across the different time points. Ziprasidone in the treatment of first episode schizophrenia in elderly patients has efficacy and less effect on blood-glucose and serum lipid metabolism.</description><identifier>ISSN: 1002-0829</identifier><identifier>DOI: 10.11919/j.issn.1002-0829.217005</identifier><identifier>PMID: 28765681</identifier><language>eng</language><publisher>China: Shanghai Municipal Bureau of Publishing</publisher><subject>Original</subject><ispartof>Shanghai Jingshen Yixue, 2017-04, Vol.29 (2), p.104-110</ispartof><rights>Shanghai Municipal Bureau of Publishing 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518257/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518257/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28765681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Jing</creatorcontrib><creatorcontrib>Pan, Xingen</creatorcontrib><creatorcontrib>Qian, Mincai</creatorcontrib><creatorcontrib>Yang, Shoukai</creatorcontrib><title>Efficacy and Metabolic Influence on Blood-Glucose and Serum Lipid of Ziprasidone in the Treatment of Elderly Patients with First-Episode Schizophrenia</title><title>Shanghai Jingshen Yixue</title><addtitle>Shanghai Arch Psychiatry</addtitle><description>As the age of the population in China rises, the occurrence of first-episode of schizophrenia in elderly persons is also gradually increasing. However, studies examining selection of therapeutic drugs for this population are relatively few. To examine the therapeutic efficacy and metabolic influence on blood-glucose and serum lipid of ziprasidone in the treatment of elderly patients with first-episode schizophrenia. Using randomized grouping, 38 elderly patients with first-episode schizophrenia were randomly divided into the ziprasidone treatment group (i.e. the study group) and the olanzapine treatment group (i.e. the control group), with 19 cases in either group respectively. The positive and negative symptoms scale (PANSS) was used to evaluate the efficacy, and adverse drug reaction scale (TESS) was used to evaluate adverse drug reactions, at the points prior to the treatment, at the end of 4th, 8th, and 12th weeks of treatment, respectively. Fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), and low density lipoprotein (LDL-c) were also measured. There was no significant difference between the two groups in PANSS score at the end of week 4, week 8 and week 12. The curative effect on the two groups was similar. The results of repeated measure ANOVA showed that there were significant differences in FBG ( , =0.001), , &lt;0.001), TG(F =488.312, &lt;0.001), and LDL-c , &lt;0.001)between the study group and the control group across the different time points. Ziprasidone in the treatment of first episode schizophrenia in elderly patients has efficacy and less effect on blood-glucose and serum lipid metabolism.</description><subject>Original</subject><issn>1002-0829</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVUctOHDEQ9CERIOAXIh9zmY3tGc_jEilBy0NaRCTIhcvIa7czjTz2xPYQbT6E72UID4W-tFRVXVVSE0I5W3He8e7L3QpT8ivOmChYK7qV4A1j8gM5eIP2yXFKd2yZpqo6yfbIvmibWtYtPyAPa2tRK72jyht6CVltg0NNL7x1M3gNNHj63YVgijM365Dgn_Aa4jzSDU5oaLD0FqeoEprggaKneQB6E0HlEXx-4tfOQHQ7-kNlXKBE_2Ae6CnGlIv1hCkYoNd6wL9hGiJ4VEfko1UuwfHLPiQ_T9c3J-fF5urs4uTbpph4y3MhWaPLhsuyEmVplOlawaEWprbAuQatS21bybVQDVetLLcgK1tWWyvq2rDl5pB8ffad5u0IRi_lonL9FHFUcdcHhf17xuPQ_wr3vZS8FbJZDD6_GMTwe4aU-xGTBueUhzCnnndikbKuE4v00_9ZbyGvzygfAWk3kHE</recordid><startdate>20170425</startdate><enddate>20170425</enddate><creator>Chen, Jing</creator><creator>Pan, Xingen</creator><creator>Qian, Mincai</creator><creator>Yang, Shoukai</creator><general>Shanghai Municipal Bureau of Publishing</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170425</creationdate><title>Efficacy and Metabolic Influence on Blood-Glucose and Serum Lipid of Ziprasidone in the Treatment of Elderly Patients with First-Episode Schizophrenia</title><author>Chen, Jing ; Pan, Xingen ; Qian, Mincai ; Yang, Shoukai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p181t-507c371534233dad9821e62d6fe11cecc3cf851c2a71a853be54f34bf266d0233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Chen, Jing</creatorcontrib><creatorcontrib>Pan, Xingen</creatorcontrib><creatorcontrib>Qian, Mincai</creatorcontrib><creatorcontrib>Yang, Shoukai</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Shanghai Jingshen Yixue</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Jing</au><au>Pan, Xingen</au><au>Qian, Mincai</au><au>Yang, Shoukai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Metabolic Influence on Blood-Glucose and Serum Lipid of Ziprasidone in the Treatment of Elderly Patients with First-Episode Schizophrenia</atitle><jtitle>Shanghai Jingshen Yixue</jtitle><addtitle>Shanghai Arch Psychiatry</addtitle><date>2017-04-25</date><risdate>2017</risdate><volume>29</volume><issue>2</issue><spage>104</spage><epage>110</epage><pages>104-110</pages><issn>1002-0829</issn><abstract>As the age of the population in China rises, the occurrence of first-episode of schizophrenia in elderly persons is also gradually increasing. However, studies examining selection of therapeutic drugs for this population are relatively few. To examine the therapeutic efficacy and metabolic influence on blood-glucose and serum lipid of ziprasidone in the treatment of elderly patients with first-episode schizophrenia. Using randomized grouping, 38 elderly patients with first-episode schizophrenia were randomly divided into the ziprasidone treatment group (i.e. the study group) and the olanzapine treatment group (i.e. the control group), with 19 cases in either group respectively. The positive and negative symptoms scale (PANSS) was used to evaluate the efficacy, and adverse drug reaction scale (TESS) was used to evaluate adverse drug reactions, at the points prior to the treatment, at the end of 4th, 8th, and 12th weeks of treatment, respectively. Fasting blood glucose (FBG), total cholesterol (TC), triglyceride (TG), and low density lipoprotein (LDL-c) were also measured. There was no significant difference between the two groups in PANSS score at the end of week 4, week 8 and week 12. The curative effect on the two groups was similar. The results of repeated measure ANOVA showed that there were significant differences in FBG ( , =0.001), , &lt;0.001), TG(F =488.312, &lt;0.001), and LDL-c , &lt;0.001)between the study group and the control group across the different time points. Ziprasidone in the treatment of first episode schizophrenia in elderly patients has efficacy and less effect on blood-glucose and serum lipid metabolism.</abstract><cop>China</cop><pub>Shanghai Municipal Bureau of Publishing</pub><pmid>28765681</pmid><doi>10.11919/j.issn.1002-0829.217005</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1002-0829
ispartof Shanghai Jingshen Yixue, 2017-04, Vol.29 (2), p.104-110
issn 1002-0829
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5518257
source PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access
subjects Original
title Efficacy and Metabolic Influence on Blood-Glucose and Serum Lipid of Ziprasidone in the Treatment of Elderly Patients with First-Episode Schizophrenia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T16%3A42%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Metabolic%20Influence%20on%20Blood-Glucose%20and%20Serum%20Lipid%20of%20Ziprasidone%20in%20the%20Treatment%20of%20Elderly%20Patients%20with%20First-Episode%20Schizophrenia&rft.jtitle=Shanghai%20Jingshen%20Yixue&rft.au=Chen,%20Jing&rft.date=2017-04-25&rft.volume=29&rft.issue=2&rft.spage=104&rft.epage=110&rft.pages=104-110&rft.issn=1002-0829&rft_id=info:doi/10.11919/j.issn.1002-0829.217005&rft_dat=%3Cproquest_pubme%3E1925510992%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1925510992&rft_id=info:pmid/28765681&rfr_iscdi=true